Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine

被引：137

作者：

Baker, CJ ^{[1
]}

Rench, MA

McInnes, P

机构：

[1] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA

[2] Baylor Coll Med, Dept Mol Virol, Houston, TX 77030 USA

[3] Baylor Coll Med, Dept Microbiol, Houston, TX 77030 USA

[4] Natl Inst Allergy & Immunol, NIH, Bethesda, MD USA

来源：

VACCINE | 2003年 / 21卷 / 24期

关键词：

group B streptococcal (GBS) infections; immunization; conjugate vaccine; pregnancy;

D O I：

10.1016/S0264-410X(03)00353-0

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Aim: To determine the safety and inummogenicity of group B streptococcal (GBS) type III CPS-TT conjugate vaccine in pregnant women. Methods: Prospective, randomized (2: 1, vaccine:placebo), double-blind, placebo-controlled trial in women at 30-32 weeks' gestation and their infants. Immune responses were measured with IgG-specific ELISA assays; killing of III GBS by 1 - and 2-month infant sera was assessed by opsonophagocytosis. Results: Immunization was well-tolerated; maternal and infant outcomes were similar in vaccine and placebo groups. III-TT conjugate elicited good levels of IgG to III CPS that were functionally active against type III GBS through age 2 months. Conclusion: Maternal immunization with GBS CPS-TT conjugates could prevent maternal, neonatal and young infant GBS disease. (C) 2003 Elsevier Science Ltd. All rights reserved.

引用

页码：3468 / 3472

页数：5

共 13 条

[11] Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines [J].